<DOC>
	<DOCNO>NCT00641537</DOCNO>
	<brief_summary>The purpose extension trial evaluate safety tolerability oral cladribine subject previously complete treatment within Trial 25643 ( CLARITY ) . This trial also explore clinical benefit prolong 192-week versus 96-week treatment .</brief_summary>
	<brief_title>CLARITY Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Randomized Trial 25643 satisfied one following : Completed randomized treatment course schedule visit full 96 week ; Did complete randomize treatment course Trial 25643 elect receive rescue treatment Rebif® , another betainterferon , glatiramer acetate complete scheduled clinic visit full 96 week ; Did complete randomize treatment course Trial 25643 , decline rescue Rebif® , another betainterferon , glatiramer acetate still complete scheduled clinic visit full 96 week ; Did complete randomize treatment course Trial 25643 , eligible rescue option Rebif® , still complete schedule clinic visit full 96 week Male female , 18 65 year age ( inclusive , time informed consent Trial 25643 ) No medical history evidence latent tuberculosis infection ( LTBI ) tuberculosis ( TB ) , evidence TB skin test chest Xray All following laboratory hematologic parameter evaluate normal ( define , inclusively ) within 28 day first dose blind study medication study Day 1 : Hemoglobin = 11.6 16.2 gram per deciliter ( g/dL ) Leukocytes ( total white blood cell ) = 4.1 12.3*10^3 per microliter Absolute lymphocyte count ( ALC ) = 1.02 3.36*10^3 per microliter Absolute neutrophil count ( ANC ) = 2.03 8.36*10^3 per microliter Platelet count = 140 450*10^3 per microliter Other protocoldefined inclusion/exclusion criterion may apply Subjects enrol Trial 25643 Subject moderate severe renal impairment Use mitoxantrone , total lymphoid irradiation , myelosuppressive therapy , campath1h , cyclophosphamide , azathioprine , methotrexate natalizumab time since Trial 25643 Use cytokine anticytokine therapy , intravenous immunoglobulin ( IVIG ) plasmapheresis time since Trial 25643 Treatment oral systemic corticosteroid adrenocorticotropic hormone within 28 day Study Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>